Fosaprepitant Cipla 150 mg Lyophilised powder for Solution for Infusion
PDF Leaflet Revision Date: 07 February 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy.
Dosage (summary)
150 mg IV on Day 1, no further doses.
Onset of Action / Duration
Onset: 30 mins, Duration: Not specified.
Special Populations
- Elderly
- Severe hepatic insufficiency
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- CYP3A4 inhibitors
- Warfarin
- Hormonal contraceptives
Contraindications
- Hypersensitivity to ingredients
- Pregnancy
- Breastfeeding
- Co-administration with pimozide, terfenadine, astemizole, cisapride
Common side effects
- Hiccups
- Fatigue
- Headache
- Constipation
- Dyspepsia
Counselling Points
- Monitor INR if on warfarin
- Use alternative contraception during and 28 days after treatment
- Do not drive if experiencing dizziness
Serious warnings
- Hypersensitivity reactions
- Severe hepatic insufficiency caution
- Infusion site reactions
Important Disclaimer
The Fosaprepitant Cipla 150 mg Lyophilised powder for Solution for Infusion professional information leaflet below is the property of Cipla Medpro and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
